Fosun Pharma: Marketing registration application for subsidiary Pertuzumab Injection approved
Fosun Pharma announced that its subsidiary, Shanghai Fosun Pharmaceutical Biotechnology Co., Ltd., has received approval from China's National Medical Products Administration for its Pertuzumab Injection. This approval covers all indications for which the originator drug is approved in China, including early-stage and metastatic breast cancer. Separately, Xiamen Tungsten announced that its subsidiary, Jinlong Rare Earth, plans to list on the Beijing Stock Exchange, aiming to raise capital for projects focused on rare earth permanent magnet materials. AI
IMPACT N/A